ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
Rhea-AI Summary
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Friday, May 15, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss first quarter 2026 financial results and business highlights. Dial-in details require event registration. A webcast replay will be available for 30 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – SPRY
On the day this news was published, SPRY declined 3.02%, reflecting a moderate negative market reaction. This price movement removed approximately $29M from the company's valuation, bringing the market cap to $921.51M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SPRY is up 2.77% with elevated volume, while key biotech peers like ATAI, CRMD, RAPP and XERS also show positive price changes today, but momentum scanner activity is limited to XERS.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Earnings call notice | Neutral | +2.3% | Announced timing for Q4 and full-year 2025 results and conferences. |
| Nov 03 | Earnings call notice | Neutral | -3.8% | Set date and time for Q3 2025 financial results discussion. |
| Aug 04 | Earnings call notice | Neutral | +1.2% | Scheduled Q2 2025 financial results conference call and webcast. |
| May 05 | Earnings call notice | Neutral | -1.4% | Announced Q1 2025 results call and webcast logistics for investors. |
| Mar 03 | Earnings call notice | Neutral | +3.2% | Outlined Q4 2024 results call and participation at investor conferences. |
Conference-call and earnings scheduling releases for SPRY have historically led to modest moves, averaging about 0.31% on the day.
Over the past year, ARS Pharmaceuticals has regularly issued conference-call and webcast notices tied to quarterly and annual results, similar to this first quarter 2026 call announcement. These releases, dated from Mar 3, 2025 through Feb 23, 2026, outlined timing for Q1, Q2, Q3 and full-year earnings discussions and occasional conference participation. Price reactions have been mixed, ranging from about -3.79% to +3.24%, underscoring that scheduling notices alone typically act as routine updates rather than major standalone catalysts.
Historical Comparison
In the past five conference-call notices, SPRY moved about 0.31% on average, suggesting today’s pre-earnings positioning fits a pattern of modest reactions to scheduling updates.
The sequence of conference-call notices from early 2025 through early 2026 reflects a consistent quarterly cadence of financial disclosures, reinforcing SPRY’s pattern of pairing earnings timing updates with broader business commentary.
Market Pulse Summary
This announcement sets the timetable for ARS Pharmaceuticals’ first quarter 2026 financial results discussion, continuing a consistent pattern of quarterly conference-call notices. Historically, similar “conferences,earnings” updates produced modest average moves of about 0.31%, suggesting these releases function mainly as logistical milestones. Investors may focus on the upcoming call for detailed revenue trends, expense trajectories, and updates on neffy’s commercialization and pipeline progress.
Key Terms
anaphylaxis medical
AI-generated analysis. Not financial advice.
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Friday, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2026 financial results and business highlights.
Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com
Monique Allaire
THRUST
monique@thrustsc.com
Media Contact:
Christy Curran
Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
